A Phase I study combining BLX-7006 and BLX-0871
Latest Information Update: 22 Jun 2025
At a glance
- Drugs BLX 0871 (Primary) ; BLX 7006 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 22 Jun 2025 New trial record
- 12 Jun 2025 According to a Biolexis Therapeutics media release, the company announced that a Phase I study combining BLX-7006 and BLX-0871 is slated to begin during the second quarter of 2026.